Thermo Fisher says it is planning to open a cell therapy development and manufacturing collaboration center in Princeton as part of a $475 million investment in its biopharma capabilities. Thermo Fisher has grown its contract development and manufacturing organization (CDMO) business firstly through its $7.2 billion acquisition of Patheon in 2017, and secondly through last year’s $1.7 billion Brammer Bio buy. The latter propelled Thermo Fisher into advanced therapy production with viral vector capacity it has since expanded upon (see…